RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Benefits of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Cardiovascular Risk
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 17
SP 27
OP 28
DO 10.1177/155989771317019
UL http://mdc.sagepub.com/content/13/17/27.abstract
AB Many studies have shown that improved glucose control in patients with diabetes reduces microvascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glucose control and were thought to reduce the risk of cardiovascular events and all-cause mortality in patients with type 2 diabetes [Monami M et al. Diabetes Obes Metab 2013]. This article discusses the Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care trial [EXAMINE; NCT00968708] and Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus [SAVOR]-TIMI 53 trial [NCT01107886] trials.